AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Anavex Life Sciences Corp... (AVXL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

8.70

-0.02 (-0.23%)

At close: Feb 20, 2025, 3:59 PM

8.65

-0.57%

After-hours: Feb 20, 2025, 06:07 PM EST

undefined% (undefined)

Bid	8.65
Market Cap	740.06M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.55
PE Ratio (ttm)	-15.82
Forward PE	n/a
Analyst	Buy

Ask	8.94
Volume	634,121
Avg. Volume (20D)	1,787,754
Open	8.72
Previous Close	8.72
Day's Range	8.62 - 8.88
52-Week Range	3.25 - 14.44
Beta	undefined

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 2, 2006

Employees 42

Stock Exchange NASDAQ

Ticker Symbol AVXL

Website https://www.anavex.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 428.74% from the latest price.

Buy 66.67%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago

+8.21%

Anavex Life Sciences shares are trading higher aft... Unlock content with Pro Subscription

2 months ago

+29.55%

Anavex Life Sciences shares are trading higher after the company announced better-than-expected Q4 financial results.

News

1 week ago · seekingalpha.com

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine s...

1 week ago · seekingalpha.com

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for the treatment of patients with Alzheimer's Disease by year-end of 2025. The global market for Alzheim...

1 week ago · seekingalpha.com

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President & CEO Sandra Boenisch...

4 weeks ago · zacks.com

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

1 month ago · zacks.com

Best Momentum Stocks to Buy for January 21st

CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.

1 month ago · zacks.com

New Strong Buy Stocks for January 21st

CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.

1 month ago · seekingalpha.com

Playing The Odds Of Anavex Alzheimer's Drug Approval

The EMA has accepted Anavex's Alzheimer's drug Blarcamesine for evaluation, with a decision expected by December 2025. Blarcamesine shows a 92% likelihood of approval by the EMA, yet investors have no...

1 month ago · zacks.com

Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL)

Anavex Life Sciences (AVXL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it...

1 month ago · zacks.com

Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?

Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.

1 month ago · zacks.com

All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy

Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Load More News